Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) Asset Utilization Ratio: 2018-2023

Historic Asset Utilization Ratio for Denali Therapeutics (DNLI) over the last 5 years, with Sep 2023 value amounting to 0.27.

  • Denali Therapeutics' Asset Utilization Ratio rose 205.17% to 0.27 in Q3 2023 from the same period last year, while for Sep 2023 it was 0.27, marking a year-over-year increase of 205.17%. This contributed to the annual value of 0.25 for FY2023, which is 233.91% up from last year.
  • As of Q3 2023, Denali Therapeutics' Asset Utilization Ratio stood at 0.27, which was up 6.07% from 0.25 recorded in Q2 2023.
  • Denali Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.27 during Q3 2023, with a 5-year trough of 0.03 in Q3 2020.
  • Over the past 3 years, Denali Therapeutics' median Asset Utilization Ratio value was 0.09 (recorded in 2022), while the average stood at 0.15.
  • Examining YoY changes over the last 5 years, Denali Therapeutics' Asset Utilization Ratio showed a top increase of 751.45% in 2021 and a maximum decrease of 88.63% in 2021.
  • Over the past 5 years, Denali Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.05 in 2019, then spiked by 443.91% to 0.25 in 2020, then tumbled by 88.63% to 0.03 in 2021, then soared by 182.83% to 0.08 in 2022, then spiked by 205.17% to 0.27 in 2023.
  • Its Asset Utilization Ratio stands at 0.27 for Q3 2023, versus 0.25 for Q2 2023 and 0.07 for Q1 2023.